Treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study
Zhang, X S, Liu, B C, Du, X, Zhang, Y L, Xu, N, Liu, X L, Li, W M, Lin, H, Liang, R, Chen, C Y, Huang, J, Yang, Y F, Zhu, H L, Pan, L, Wang, X D, Li, G H, Liu, Z G, Zhang, Y Q, Liu, Z F, Hu, J D, Liu, C S, Li, F, Yang, W, Meng, L, Han, Y Q, Lin, L E, Zhao, Z Y, Tu, C Q, Zheng, C F, Bai, Y L, Zhou, Z P, Chen, S N, Qiu, H Y, Yang, L J, Sun, X L, Sun, H, Zhou, L, Liu, Z L, Wang, D Y, Guo, J X, Pang, L P, Zeng, Q S, Suo, X H, Zhang, W H, Zheng, Y J, Jiang, Q
Published in Zhōnghuá xuèyèxué zázhì (14.03.2024)
Published in Zhōnghuá xuèyèxué zázhì (14.03.2024)
Get full text
Journal Article
To compare the efficacy and incidence of severe hematological adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia
Zhang, X S, Liu, B C, Du, X, Zhang, Y L, Xu, N, Liu, X L, Li, W M, Lin, H, Liang, R, Chen, C Y, Huang, J, Yang, Y F, Zhu, H L, Pan, L, Wang, X D, Li, G H, Liu, Z G, Zhang, Y Q, Liu, Z F, Hu, J D, Liu, C S, Li, F, Yang, W, Meng, L, Han, Y Q, Lin, L E, Zhao, Z Y, Tu, C Q, Zheng, C F, Bai, Y L, Zhou, Z P, Chen, S N, Qiu, H Y, Yang, L J, Sun, X L, Sun, H, Zhou, L, Liu, Z L, Wang, D Y, Guo, J X, Pang, L P, Zeng, Q S, Suo, X H, Zhang, W H, Zheng, Y J, Jiang, Q
Published in Zhōnghuá xuèyèxué zázhì (14.09.2023)
Published in Zhōnghuá xuèyèxué zázhì (14.09.2023)
Get full text
Journal Article